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manipulations of the utilization of metabolic substrates should result
in an improvement of myocardial ischemia and of left ventricular
function.
Therefore, the metabolic changes of diabetes alter myocardial
metabolism reducing cardiac susceptibility to ischemic stimuli and
cardiac performance. In diabetic coronary patients the episodes of
transient myocardial ischemia coupled with the chronic myocardial
hypoperfusion cause a progressive decline of left ventricular
function. The inhibition of FFA oxidation improves cardiac metabo-
lism at rest, increases the cardiac ischemic and therefore reduces the
decline of left ventricular function due to chronic hypoperfusion and
repetitive episodes of myocardial ischemia.
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Bergamot (Citrus Bergamia) is an endemic plant of Calabrian region
in Southern Italy. To date, 95% ofworldwide bergamot production occurs
in the Ionic area of Calabria, where soil characteristics and pH (b6.5–7.5)
are particularly suitable for its cultivation.
Bergamot essential oil (BEO) is made up of a volatile fraction and a
non-volatile residue. Volatile components make up approximately 93–
96% byweight of bergamot oil, while the non-volatile residue represents
the remaining 4–7%. The non-volatile fraction is a mixture of monoter-
pene and sesquiterpene hydrocarbons (such as limonene, γ-terpinene,
and β-pinene) and their oxygenated derivatives (linalool and linalyl
acetate). The non-volatile (4–7% of total) fraction containing coumarins
and psoralens [such as bergapten (5-methoxypsoralen) and berga-
mottine (5-geranyloxypsoralen)]. The non-volatile residue, which
inﬂuences the olfactory properties of the oil, contains waxes and
polymethoxylated ﬂavones other than about 0.2% bergapten which is
responsible for the phototoxicity of BEO. The bergapten-free extract of
the essence (BEO-BF) together with a natural essence deprived of the
hydrocarbon fraction and of bergapten (BEO-HF/BF) are prepared by
extractive industries for perfumery and cosmetic uses [2,3].
Bergamot differs from other citrus fruits not only because of the
composition of these ﬂavonoids, but also because of their particularly
high content. Some of the ﬂavonoids such as naringin, present also in
grapefruit, have already been shown to be active in animal models of
atherosclerosis, while neoeriocitrin and rutin exhibited the strongest
capacity to inhibit LDL oxidation. Importantly, bergamot juice is rich in 3-
hydroxy-3-methylglutaryl neohesperidosides of hesperetin (bru-
tieridine) and naringenin (melitidine) with ability to inhibit HMG-CoA
reductase. These compounds most likely contribute to the important
hypolipemic effects of bergamot juice and vasoprotective effects of
bergamot oil derivatives in rats and in humans as demonstrated by
recent clinical studies carried out in patients treated with bergamot-
derived polyphenolic fraction (BPF) obtained concentrating bergamot
juice in a form of powder, enriched in ﬂavonoids.
Epidemiologic studies have demonstrated that a Mediterranean diet
rich in olive oil is associated with decrease in risk for cardiovascular
disease, obesity, and diabetes. Although some of the protection may be
from the unsaturated fatty acid components of such a diet, additional
smallmolecules found in olive oil and olive plantsmay confer protection,
including the polyphenol oleuropein and hydroxytyrosol.
The two main sources of olive polyphenols are olive leaves and
the waste from the olive oil industry. Olive leaves have the highest
antioxidant and scavenging power among the different parts of the
olive tree. There are ﬁve groups of phenolic compounds principally
present in olive leaves: oleuropeosides (oleuropein and ver-
bascoside); ﬂavones (luteolin-7-glucoside, apigenin-7-glucoside,
diosmetin-7- glucoside, luteolin, and diosmetin); ﬂavonols (rutin);
ﬂavan-3-ols (catechin), and substituted phenols (tyrosol, hydroxy-
tyrosol, vanillin, vanillic acid, and caffeic acid). The most abundant
compound in olive leaves is oleuropein, followed by hydroxytyrosol,
a precursor of oleuropein, the ﬂavone-7-glucosides of luteolin and
apigenin, and verbascoside, a conjugated glucoside of hydroxytyrosol
and caffeic acid.
Oleuropein prevents cardiac disease by protecting membrane
from lipid oxidation, by affecting coronary blood vessel dilation, by
exerting antiarhythmic action, by improving lipid metabolism, by
protecting enzymes, by preventing hypertensive cell death in cancer
patients and by its antiviral properties.
In the current review, we want to highlight the potential
beneﬁcial effects of synergistic action of BPF and oleuropein.
There is evidence to suggest that the anti-hypertensive activity of
the olive leaf extract lies probably in its content of oleuropein acting
synergistically with other active substances to exert both ACE
inhibitory and calcium channel blocking activities.
The anti-hypertensive and cholesterol-lowering actions hypoth-
esized for oleuropein suggest its potential synergistically action with
BPF, able to induce in patients both hypolipemic and hypoglycaemic
effects other than an improvement of reactive vasodilatation. This
latter action also underlines an improvement of endothelial function
in patients at risk of atherosclerosis.
Since oxidative stress has been shown to reduce reactive NO-
dependent vasodilatation, it is likely that BPF may well attenuate
overproduction of oxygen reactive species in the vascular wall
thereby restoring the imbalanced endothelial function in hyperlipe-
mic patients.
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Background: Overproduction of oxidized-low density lipoproteins
(oxyLDL) has been found to contribute in endothelial cell (EC)
dysfunction thereby leading to atherosclerosis development and
progression. In particular, oxyLDL lead to apoptotic cell death of EC via
oxidative stress production, mostly subsequent to overexpression of the
scavenger receptor LOX-1. Here, we hypothesize that LOX-1 expression
in EC represents a crucial event which attenuates protective autophagic
response, thereby enhancing programmed endothelial cell death.
Methods and results: Bovine aortic endothelial cells (BAEC) in culture
were exposed to oxyLDL (1–100 μM). After 48 h incubation, oxyLDL
produced apoptotic cell death of BAEC as detected by FACS analysis, an
effect counteracted by antioxidant N-acetyl-cysteine (NAC) as well as by
the NO-donor SNAP. OxyLDL-induced apoptotic cell death was also
accompanied by reduced VEGF-dependent phosphorylation of constitu-
tive NO synthase (cNOS) in BAEC and consistent attenuation of
autophagic response as detected by expression of beclin-1 and LC3,
two reliable biomarkers of autophagy. Moreover, silencing LOX-1
receptor signiﬁcantly restored LC3 expression in oxyLDL-treated BAEC,
thus suggesting a key role of LOX-1 overproduction in oxyLDL-induced
endothelial dysfunction.
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Conclusions: OxyLDL leads to impaired NO generation and
apoptotic cell death in BAEC. This effect occurs via overexpression
of LOX-1 and the subsequent attenuation of protective autophagic
response thereby contributing in the pathophysiology of oxyLDL-
induced endothelial dysfunction which characterizes early stages of
atherosclerotic process.
doi:10.1016/j.ijcme.2015.05.005
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Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), one
of the scavenger receptors for oxidized low density lipoprotein (ox-LDL),
plays a crucial role in signaling pathways involved in the process of
oxidative stress and inﬂammation. As evidence supporting the vital role
of LOX-1 keeps accumulating, there is growing interest in LOX-1 as a
potential therapeutic target. Here, we review the discovery and genetics
of LOX-1, describe existing evidence supporting the role of LOX-1 in
atherogenesis and its major complication- myocardial ischemia, and
summarize its modulation by some naturally occurring compounds that
could be of therapeutic use.
Ox-LDL/LOX-1 relationship appears to be an important player in
the development of atherosclerosis and its sequelae, such as MI and
cardiac remodeling. The scavenger receptor LOX-1 activates most, if
not all, signaling from the beginning to culmination of major life-
threatening events related to this malady. From genetic studies, it is
quite evident that certain individuals have propensity to develop
CAD-related events. Since the current therapies of coronary heart
disease, mainly LDL-cholesterol lowering drugs, are ineffective in a
large number of patients, there is need for new targets that focus on
the underlying signals of the disease process. A host of strategies are
being proposed that would either block oxidation of LDL-cholesterol
and/or reduce the expression of LOX-1. While the development of
these strategies is eagerly awaited, some naturally occurring
compounds appear quite promising and deserve clinical trials.
doi:10.1016/j.ijcme.2015.05.006
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The endothelium regulates vascular homoeostasis through local
elaboration of mediators that modulate vascular tone, platelet
adhesion, inﬂammation, ﬁbrinolysis, and vascular growth. Impaired
vascular function contributes to the pathogenesis of atherosclerosis
and acute coronary syndromes. Impaired endothelial function is
associated with atherothrombotic risk factors and atherothrombotic
disease, is pathophysiologically linked to acute cardiovascular
syndromes. A central feature of impaired endothelial function in
the presence of cardiac risk factors and under pathological conditions
is impairment in endothelium-derived bioactivity.
Nitric oxide is produced in endothelial cells from the conversion
of l-arginine to l-citrulline through the activity of (endothelial) nitric
oxide synthase. EDNO regulates vascular tone through a dilator
action on vascular smooth muscle cells that depends on soluble
guanylyl cyclase activation and consequent increase in guanosine
monophosphate. Additional antiatherogenic functions of EDNO relate
to inhibition of platelet activity, leucocyte adhesion, and vascular
smooth muscle cell proliferation. Mechanisms underlying impaired
endothelial function in various disease states such as hypertension,
diabetes mellitus, hypercholesterolaemia, and atherosclerosis are
likely multifactorial. There is growing evidence that oxidative stress
(deﬁned as an imbalance between endogenous oxidants and
antioxidants in favour of the former) contributes to mechanisms of
vascular dysfunction. These observations ﬁt well with the recogni-
tion that increased oxidative stress may be central to the atherogenic
process.
Although the mechanism of oxidative modiﬁcation of LDL
remains unknown, the importance of oxidation can be seen by the
presence of oxidized LDL in atherosclerotic lesions. Experimentally,
the amount of oxidized LDL is reﬂective of the atherosclerotic
burden. Oxidized LDL induces a series of atherogenic processes,
including transcription of proatherogenic genes, production of
matrix metalloproteinases and tissue factor, antagonism of endothe-
lial cell production of NO, and promotion of vascular smooth muscle
cell apoptosis. The augmented production of superoxide anion also
rapidly reacts with NO to produce peroxynitrite, a potent oxidant.
However, large trials of antioxidant vitamins, including the
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto
miocardico (GISSI) Prevention Trial, the Heart Outcomes Prevention
Evaluation Study (HOPE), and the Heart Protection Study (HPS),
have not demonstrated any reduction in clinical events with
antioxidant vitamin E therapy. The antioxidants used in these trials,
however, have limitations that may have precluded an adequate test
of the hypothesis. Conventional antiplatelet therapy has also
antioxidant effects by virtue of its ability to limit production of ROS
by activated platelets. The importance of oxidative stress in the
pathogenesis of atherosclerosis makes clear that the limitations of
current therapies should not conclude therapeutic interest in this
area but foster investigation into new avenues of treatment.
There is considerable need for additional investigation into the
basic mechanisms of atherosclerosis. It is important to clarify the
differential role of HDL cholesterol metabolism and other lipid
disturbances as well as the biomechanical and rheologic factors in
development and progression of disease in the noncoronary
circulations. Greater research is needed in understanding regional
differences in plaque formation and clinical manifestations of
disease. Genetic variability across individuals and populations merits
additional exploration using genomics and proteomics. Pathophysi-
ological responses to changes in metabolic demand such as exercise
and factors that determine development of collateral vessels and
angiogenesis need greater attention. In particular, the interaction
between reduced oxygen and substrate delivery and skeletal muscle,
neurological, and metabolic function needs additional study. There is
a need for improved functional imaging and biomarkers of disease
progression and unstable patterns of atherosclerosis to assist in
understanding of regional disease pathophysiology.
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